Renaming Palliative Cancer Therapies: Call It What It Is
This commentary explores the language choices that oncology providers make when discussing cancer therapy goals.
This commentary explores the language choices that oncology providers make when discussing cancer therapy goals.
Disrupting Jagged2 signaling reprograms immune cells to fight tumors
Show How This Is Building Me, Ep Camidge and Rimel on the Importance of Cultivating Inclusive Gynecologic Oncology Practices – Apr 15, 2024
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of…
The Biden administration has—for the second time—delayed the decision on a proposed FDA rule that would ban menthol cigarettes and all flavors in cigars. To…
Bladder Cancer statistics
All women should start screening for breast cancer at age 40, with biennial screening continuing through age 74, the U.S. Preventive Services Task Force said…
Mark D. Tyson, II, MD, MPH, discusses the background of the phase 3 BOND-003 study evaluating cretostimogene grenadenorepvec in patients with high-risk Bacillus Calmette-Guérin-unresponsive non-muscle-invasive…
In this issue of Blood, Fuchs et al1 have used T-cell biology, coupled with Genome Wide Association Studies (GWAS) and computational leverage of public dat
An abstract is unavailable.
Cancer drugs approved under the FDA’s Real-Time Oncology Review program may not be supported by adequate trial data, researchers suggested.